Status In progress
Process CDF Review
ID number 3880

Provisional Schedule

Committee meeting: 1 08 December 2021
Expected publication 02 March 2022

Project Team

Project lead Daniel Davies

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Bristol-Myers Squibb
Others Department of Health
  NHS Greater Preston CCG
  NHS Surrey Heath CCG
  NHS England
  Welsh Government
Patient carer groups Kidney Cancer UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists


Associated public health groups None
Comparator companies Ipsen (cabozantinib)
  Pfizer (sunitinib)
  Roche Products (interferon-alfa 2a)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
12 August 2021 Invitation to participate
12 August 2021 In progress. In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance